CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 65 enrolled
Drug / intervention
Empagliflozin 10 mg Tab +1 moredrug
Likely dose
Empagliflozin 10 mg Tabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03030222
NCT03030222Phase 4Completed
CompareCT.gov

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure

Saint Luke's Health System·interventional·Posted Jan 24, 2017·Updated Dec 9, 2021

In Brief

A Phase 4 clinical trial evaluating Empagliflozin 10 mg Tab and Placebo Oral Tablet for Heart Failure. Completed, enrolled 65 participants across 10 sites.

Detailed Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device (a wireless hemodynamic monitoring system) implanted for non-study related clinical reasons.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 24, 2017
Enrollment StartJul 5, 2017
Primary CompletionMar 10, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.4 years ago

Interventions

Empagliflozin 10 mg Tabdrug

Empagliflozin 10 mg Tab

Placebo Oral Tabletdrug

Empagliflozin matching placebo